The chairman of Cambridge Therapeutics, John Klein has facilitated FDA approval of more than 300 generic drugs throughout his extensive career in the pharmaceutical industry. John Klein is also the chairman and CEO of Bilogix, LLC, in Alpine, NJ.
Bilogix is an enterprise performance management (EPM) firm, meaning that it offers proprietary services designed to boost business clients’ operational performance and overall efficiency with an emphasis on information-technology infrastructure. EPM processes help measure, analyze, and estimate organizational performance and add value to businesses by directing the appropriate resources to achieve desired objectives. While EPM shares some commonalities with data processing tools like analytics and business intelligence (BI), they differ in their approach.
Most notably, BI and analytics tools focus on highlighting relevant information pertaining to daily operations so leaders can make informed decisions. In this way, they are generally reactive. Conversely, EPM tools are proactive. This is because they allow organizations to assess overall performance and make necessary changes based on information and data as it becomes available. Both BI and EPM have their benefits, and companies are increasingly leveraging both to track and refine operations.
Serving as the chairman of Cambridge Therapeutics in Alpine, NJ, John Klein has more than 20 years of experience in pharmaceutical manufacturing. In addition to leading Cambridge Therapeutics, John Klein functions as the chairman and CEO of Bilogix, an enterprise performance management (EPM) firm.
With a focus on helping business clients achieve maximum organizational efficiency and increase profits, Bilogix offers comprehensive analysis of operational data, as well as customized insights on improving business management. In today’s competitive business environment, EPM software and consulting services are considered necessary for organizations that want to boost their digital capabilities and remain profitable.
EPM analysis links financial data with performance metrics, which often reveals new strategies for generating revenue, as well as other steps for streamlining operations and cutting unnecessary costs. EPM solutions can also help managers and executives become more savvy as they use digital tools to monitor financial performance in real time and identify sales trends. Organizations of all types can benefit from an EPM solution in order to better understand their enterprise’s financial data and make more informed business decisions.
An experienced pharmaceutical executive based in Alpine, NJ, John Klein is the chairman of Cambridge Therapeutics. Credited with obtaining US Food and Drug Administration approval for over 300 generic drugs, John Klein remains up to date on health-related developments in NJ.
A new program based in Paterson, NJ, aims to improve health outcomes by offering affordable housing to people in need. In collaboration with the state, St. Joseph’s Health will provide increased aid to frequent visitors to its emergency departments by helping to transform a nearby parking lot into a first-of-its-kind affordable-housing development. The property site is located across the street from St. Joseph’s University Medical Center. When finished, it will have 70 residential units that include one- to three-bedroom apartments. Residents will be eligible for housing vouchers to subsidize their rent. The venture is part of the Hospital Housing Partnership Program, which will establish a support system to low-income individuals.
While most of the financing comes from St. Joseph’s, the Housing and Mortgage Finance Agency will provide $12 million in funding, and the New Jersey Development Corporation will manage the construction at the site. As of July 2019, eight other hospitals expressed interest in joining the Hospital Housing Partnership Program.
New Jersey-based executive John Klein serves as the chairman of Cambridge Therapeutics. In addition to overseeing operations at Cambridge Therapeutics, John Klein takes an active interest in developments concerning health care and health policy.
New Jersey officials announced new rules intended to expand access to the state’s medical marijuana program, following the directive set in an executive order by Governor Phil Murphy. In addition to removing bureaucratic hurdles for young patients, the new policies will allow patients with a wider variety of diseases and ailments to access medical marijuana.
Taking effect May 20, 2019, the reforms also relax some of the regulations governing businesses that grow, produce, and sell medicinal cannabis. Other policies already in effect but now codified include reducing medical cannabis costs for patients and permitting doctors to prescribe medical marijuana without being named publicly as a physician participating in the program.